• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Dynamics Special Purpose Corp. (Amendment)

    4/5/22 11:21:36 AM ET
    $DYNS
    Get the next $DYNS alert in real time by email
    SC 13G/A 1 Dynamics_Special_Purpose_C.htm FILING DYNAMICS SPECIAL PURPOSE CORP Schedule 13G


     
    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
    (Amendment No. 01)*
     
    Dynamics Special Purpose Corp 

    (Name of Issuer)
     
    Class A common stock, par value $0.0001 per share

    (Title of Class of Securities)
     
    268010105

    (CUSIP Number)
     
    March 31, 2022

    (Date of Event Which Requires Filing of this Statement)
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
         x  Rule 13d-1(b)
     
         o  Rule 13d-1(c)
     
         o  Rule 13d-1(d)
     
    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     


     
     

     
     
    CUSIP No.  268010105            
     
               
    1   NAMES OF REPORTING PERSONS

    I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
      JPMORGAN CHASE & CO.

    13-2624428
         
    2   CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)



      (a)   o
      (b)   o
         
    3   SEC USE ONLY
       
       
         
    4   CITIZENSHIP OR PLACE OF ORGANIZATION
       
     
           
    NUMBER OF SHARES BENEFICIALLY  OWNED BY EACH REPORTING PERSON WITH:  5   SOLE VOTING POWER
       
      551,978
         
    6   SHARED VOTING POWER
       
      0
         
    7   SOLE DISPOSITIVE POWER
       
      551,978
         
    8   SHARED DISPOSITIVE POWER
       
      0
         
    9   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
      551,978
         
    10   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
      o
         
    11   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
      2.3 %
         
    12   TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
     
     

    FOOTNOTES
       
     
     
     

     
     
    Item 1.


     
    (a)
    Name of Issuer
     
     
    Dynamics Special Purpose Corp


     
    (b)
    Address of Issuer’s Principal Executive Offices
     
     
    2875 El Camino Real
    Redwood City, CA 94061


    Item 2.


     
    (a)
    Name of Person Filing
     
     
    JPMORGAN CHASE & CO.


     
    (b)
    Address of Principal Business Office or, if none, Residence
     
     
    383 Madison Avenue
    New York, NY 10179


     
    (c)
    Citizenship
     
     
    Delaware


     
    (d)
    Title of Class of Securities
     
     
    Class A common stock, par value $0.0001 per share


     
    (e)
    CUSIP Number
     
     
    268010105


     
    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:


     
    (a)
    o
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).


     
    (b)
    o
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).


     
    (c)
    o
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).


     
    (d)
    o
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).


     
    (e)
    o
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);


     
    (f)
    o
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);


     
    (g)
    x
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);


     
    (h)
    o
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);


     
    (i)
    o
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);


     
    (j)
    o
    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).


     
    (k)
    o
    A group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:


     
     
     

     
     
    Item 4.
    Ownership.
     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.


     
    (a)
    Amount beneficially owned: 551,978


     
    (b)
    Percent of class: 2.3 %


     
    (c)
    Number of shares as to which the person has:


     
    (i)
    Sole power to vote or to direct the vote: 551,978


     
    (ii)
    Shared power to vote or to direct the vote: 0


     
    (iii)
    Sole power to dispose or to direct the disposition of: 551,978


     
    (iv)
    Shared power to dispose or to direct the disposition of: 0


    Item 5.
    Ownership of Five Percent or Less of a Class
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following x .
     
     
     
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.
     
    Not Applicable
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
     
    J.P. Morgan Securities LLC
     
    Item 8.
    Identification and Classification of Members of the Group
     
    Not Applicable
     
    Item 9.
    Notice of Dissolution of Group
     
    Not Applicable
     
     
     

     
     
     
    Item 10.
    Certification
       
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.
     
     


    SIGNATURE


    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
     
      JPMORGAN CHASE & CO.

     
           
    Date: April 05, 2022
    By:
    /s/  Rachel Tsvaygoft  
        Name: Rachel Tsvaygoft  
        Title:  Vice President  
           
     
    Footnotes:


    Attention:
    Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)
     
     



    Get the next $DYNS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DYNS

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $DYNS
    SEC Filings

    View All

    Dynamics Special Purpose Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Senti Biosciences, Inc. (0001854270) (Filer)

    1/9/23 7:54:29 AM ET
    $DYNS

    SEC Form 424B3 filed by Dynamics Special Purpose Corp.

    424B3 - Senti Biosciences, Inc. (0001854270) (Filer)

    12/12/22 8:23:31 AM ET
    $DYNS

    SEC Form 424B3 filed by Dynamics Special Purpose Corp.

    424B3 - Senti Biosciences, Inc. (0001854270) (Filer)

    12/12/22 8:20:56 AM ET
    $DYNS

    $DYNS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Knobelman Deborah was granted 30,000 shares

    4 - Senti Biosciences, Inc. (0001854270) (Issuer)

    10/4/22 4:47:13 PM ET
    $DYNS

    SEC Form 4 filed by Rajangam Kanya

    4 - Senti Biosciences, Inc. (0001854270) (Issuer)

    7/20/22 6:00:12 PM ET
    $DYNS

    SEC Form 4 filed by Mathers Edward T

    4 - Senti Biosciences, Inc. (0001854270) (Issuer)

    7/15/22 6:09:58 PM ET
    $DYNS

    $DYNS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Senti Bio Debuts as Publicly Traded Company Focused on Developing Next-Generation Cell and Gene Therapies Engineered with Gene Circuits

    - Business combination with Dynamics Special Purpose Corp. completed today; gross proceeds from transaction to Senti Bio expected to total approximately $156.5 million - - Combined company Senti Bio will be listed on the Nasdaq Global Market under ticker symbol "SNTI" - - IND filings for preclinical oncology candidates SENTI-202 and SENTI-301 anticipated in 2023 - SOUTH SAN FRANCISCO, Calif., June 09, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. ("Senti Bio"), a biotechnology company developing next-generation cell and gene therapies using its proprietary gene circuit platform, today announced the completion of its business combination with Dynamics Special Purpose Corp. (("D

    6/9/22 7:30:00 AM ET
    $DYNS

    Senti Bio to Present at the 40th Annual J.P. Morgan Virtual Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. ("Senti Bio"), a leading Gene Circuit company today announced that Tim Lu, MD, PhD, Chief Executive Officer and Co-Founder, will present a corporate overview at the 40th Annual J.P. Morgan Virtual Healthcare Conference on Tuesday, January 11, 2022 at 2:00 p.m. EST. Senti Bio uses its Gene Circuit platform to program cell and gene therapies with potentially enhanced capabilities. Gene Circuits, which are created via synthetic biology and encoded as novel and proprietary combinations of DNA sequences, enable cells to sense inputs, compute decisions with biological logic, and respond to disease environment

    1/6/22 8:02:00 AM ET
    $DYNS

    Senti Bio and Dynamics Special Purpose Corp. Announce Business Combination Agreement to Create Publicly Listed Company Pioneering Gene Circuit-Engineered Cell and Gene Therapies

    - Business combination with Dynamics Special Purpose Corp. (NASDAQ:DYNS) is expected to provide more than $296 million in gross proceeds, over $153 million of which is fully committed in a common stock Private Investment in Public Equity ("PIPE") financing and from non-redemption agreements -  - Over $86 million in non-redemption agreements committed from existing Dynamics investors including funds managed by ARK Investment Management LLC, funds and accounts managed by Counterpoint Global (Morgan Stanley Investment Management), Invus, and T. Rowe Price funds - - Over $66 million in a PIPE financing committed from institutional investors including 8VC, Amgen Ventures, funds and accounts man

    12/20/21 7:05:00 AM ET
    $DYNS
    $ILMN
    $MRNA
    Medical Specialities
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: Laboratory Analytical Instruments

    $DYNS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Dynamics Special Purpose Corp.

    SC 13D - Senti Biosciences, Inc. (0001854270) (Subject)

    7/15/22 5:24:53 PM ET
    $DYNS

    SEC Form SC 13G/A filed by Dynamics Special Purpose Corp. (Amendment)

    SC 13G/A - Dynamics Special Purpose Corp. (0001854270) (Subject)

    4/5/22 11:21:36 AM ET
    $DYNS

    SEC Form SC 13G/A filed by Dynamics Special Purpose Corp. (Amendment)

    SC 13G/A - Dynamics Special Purpose Corp. (0001854270) (Subject)

    2/14/22 5:07:15 PM ET
    $DYNS